Cargando…

Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy

While modified FOLFIRINOX therapy is effective for treating advanced pancreatic cancer, it frequently causes severe neutropenia. The present study investigated the effect of severe neutropenia on clinical outcomes in advanced pancreatic cancer patients who received modified FOLFIRINOX. The study sub...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamada, Yunami, Fujii, Hironori, Watanabe, Daichi, Kato-Hayashi, Hiroko, Ohata, Koichi, Kobayashi, Ryo, Ishihara, Takuma, Uemura, Shinya, Iwashita, Takuji, Shimizu, Masahito, Suzuki, Akio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265962/ https://www.ncbi.nlm.nih.gov/pubmed/30453583 http://dx.doi.org/10.3390/cancers10110454

Ejemplares similares

Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
por: Sadaka, Shiori, et al.
Publicado: (2022)

Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy — a retrospective observational study
por: Fujii, Hironori, et al.
Publicado: (2021)

Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center
por: Mita, Naoki, et al.
Publicado: (2021)

A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer
por: Yoshida, Kensaku, et al.
Publicado: (2017)

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
por: Mita, Naoki, et al.
Publicado: (2019)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
por: Fujii, Hironori, et al.
Publicado: (2018)

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias
por: Watanabe, Daichi, et al.
Publicado: (2023)

Contrast enhancement for undetectable intrahepatic bile duct to facilitate endoscopic ultrasound-guided hepaticogastrostomy
por: Iwashita, Takuji, et al.
Publicado: (2023)

Efficacy of the Endoscopic Ultrasound-first Approach in Patients with Suspected Common Bile Duct Stone to Avoid Unnecessary Endoscopic Retrograde Cholangiopancreatography
por: Maruta, Akinori, et al.
Publicado: (2019)

Micro-RNA Analysis of Pancreatic Cyst Fluid for Diagnosing Malignant Transformation of Intraductal Papillary Mucinous Neoplasm by Comparing Intraductal Papillary Mucinous Adenoma and Carcinoma
por: Shirakami, Yohei, et al.
Publicado: (2021)

Evaluation of preoperative diagnostic methods for resectable pancreatic cancer: a diagnostic capability and impact on the prognosis of endoscopic ultrasound-guided fine needle aspiration
por: Maruta, Akinori, et al.
Publicado: (2021)

Efficacy of Contrast-Enhanced Endoscopic Ultrasonography for the Differentiation of Non-Hodgkin’s Lymphoma: A Single-Center Retrospective Cohort Study
por: Yoshida, Kensaku, et al.
Publicado: (2023)

EUS-guided hybrid rendezvous technique as salvage for standard rendezvous with intra-hepatic bile duct approach
por: Iwashita, Takuji, et al.
Publicado: (2018)

G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans
por: Cardot-Ruffino, Victoire, et al.
Publicado: (2023)

Endoscopic ultrasound-guided fine-needle aspiration of pelvic lesions via the upper and lower gastrointestinal tract approaches
por: Mita, Naoki, et al.
Publicado: (2021)

Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy
por: Hirose, Chiemi, et al.
Publicado: (2020)

Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Focal Liver Lesions: The Expanding Light Over the Shadow
por: Iwashita, Takuji, et al.
Publicado: (2021)

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)

Long- and short-term outcomes of balloon dilation for benign choledochojejunal anastomotic stricture using balloon endoscopy-assisted ERCP: a multi-center retrospective cohort study
por: Iwasa, Yuhei, et al.
Publicado: (2023)

Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?
por: Fernandes, Gustavo dos Santos, et al.
Publicado: (2019)

Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer
por: Irisawa, Ai, et al.
Publicado: (2022)

Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy
por: Fujii, Hironori, et al.
Publicado: (2022)

Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX
por: Inoue, Naonori, et al.
Publicado: (2021)

Automatic Segmentation of Pancreatic Tumors Using Deep Learning on a Video Image of Contrast-Enhanced Endoscopic Ultrasound
por: Iwasa, Yuhei, et al.
Publicado: (2021)

Preoperative perihilar cholangiocarcinoma assessment using virtual endoscopic imaging magnetic resonance cholangioscopy
por: Okuno, Mitsuru, et al.
Publicado: (2021)

Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study
por: Keum, Jiyoung, et al.
Publicado: (2022)

Drainage of Afferent Limb Obstruction via the Trans-gastric-bile Duct Formed after Endoscopic Ultrasound-guided Hepaticogastrostomy in a Patient with Pancreatic Cancer
por: Mabuchi, Masatoshi, et al.
Publicado: (2022)

Endoscopic Internalization by Cutting the Endoscopic Transpapillary Nasogallbladder Drainage Tube in Management of Acute Cholecystitis: A Retrospective Multicenter Cohort Study
por: Maruta, Akinori, et al.
Publicado: (2022)

Controlling nutritional status score during hospitalization as a predictor of clinical outcome in patients with aneurysmal subarachnoid hemorrhage
por: Shimizu, Shinya, et al.
Publicado: (2023)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

A Solid Pseudopapillary Neoplasm of the Pancreas Associated With IgG4-Related Pancreatitis: A Case Report
por: Hatano, Yuichiro, et al.
Publicado: (2016)

A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Sasaki, Mitsuhito, et al.
Publicado: (2021)

SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy
por: Racu, Marie-Lucie, et al.
Publicado: (2023)

Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
por: Nakamura, Fumihiko, et al.
Publicado: (2019)

Endoscopic Transpapillary Gallbladder Drainage for Recurrent Cholecystitis after Covered Self-expandable Metal Stent Placement for Unresectable Malignant Biliary Obstruction
por: Maruta, Akinori, et al.
Publicado: (2022)

Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX
por: Shirasu, Hiromichi, et al.
Publicado: (2018)

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019)

Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
por: Hino, Kaori, et al.
Publicado: (2022)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
por: Sawada, Masashi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l9pv2gsh4gdj5spv0cdcsbeutf